PDMR Dealing
November 30 2017 - 8:42AM
Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative therapies for respiratory diseases,
announces that, on November 29, 2017, Dr. David Ebsworth,
Non-Executive Chairman of the Company, purchased 10,000 ordinary
shares of 5 pence each in the Company (the “Ordinary Shares”) at a
price of 106.85 pence per Ordinary Share. Following the
acquisition, Dr. Ebsworth will have an interest in the Company of
135,787 Ordinary Shares, representing 0.13% of the Company’s issued
share capital.
The notification set out below is provided in
accordance with the requirements of the EU Market Abuse
Regulation.
|
|
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
David Ebsworth |
2 |
Reason for the notification |
a) |
Position/status |
Non-Executive Chairman |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Verona Pharma plc |
b) |
LEI |
213800EVI6O6J3TIAL06 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
|
|
|
|
Identification code |
GB00BYW2KH80 |
|
|
|
b) |
Nature of the transaction |
David Ebsworth purchased 10,000 Ordinary Shares |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
106.85 pence per Ordinary Share |
10,000 Ordinary Shares |
|
|
|
d) |
Aggregated information |
N/A |
|
|
|
|
- Aggregated volume |
|
|
|
|
|
- Price |
|
|
|
|
e) |
Date of the transaction |
29 November 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM |
|
|
|
For further information, please contact:
Verona Pharma plc |
Tel:
+44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer |
info@veronapharma.com |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviserand UK
Broker) |
Tel:
+44 (0) 20 7710 7600SNELVeronaPharma@stifel.com |
Stewart Wallace / Jonathan Senior / Ben Maddison |
|
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024